Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06522022 · ClinicalTrials.gov registry record · NA

PTSD Screening in Pregnant Black Women

A NA study of PTSD and Pregnancy Early, sponsored by Emory University.

Recruiting
Registry status
NA
Development phase
804
Enrollment target
2
Study locations

NCT06522022: Recruiting NA study of PTSD and Pregnancy Early, sponsored by Emory University.

NCT06522022 is a NA study of PTSD and Pregnancy Early that is actively recruiting participants, run by Emory University. The registered enrollment target is 804 participants, above the 297-participant average among 154 other PTSD trials with a reported enrollment target (171% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06522022, a NA study of PTSD and Pregnancy Early, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
NA
Development phase
804 participants
Enrollment target
2
Study locations

Study Summary

This study will compare the effectiveness of two active screening interventions in improving post-traumatic stress disorder (PTSD) symptoms, maternal perinatal care utilization, satisfaction utilization of mental healthcare services, and maternal health and birth-related outcomes for Black pregnant women.

Primary Outcome

Researchers will use the PTSD Checklist for DSM-5 (PCL-5) to measure PTSD symptoms, a well-validated and widely used 21-item measure that assesses the frequency of current PTSD symptoms. Participants report how often they have been bothered by specific symptoms of PTSD on a scale of 0 (not at all) to 4 (extremely). The total symptom severity score ranges from 0 to 80. A provisional PTSD diagnosis can be made and a PCL-5 cut-point score of 33 is recommended.

Conditions Studied

Interventions

  • BEHAVIORAL Culturally Responsive SBIRT for OB
  • BEHAVIORAL Brief Screening for PTSD

Study Locations (2)

Georgia

  • Grady Health System - Atlanta

Missouri

  • Truman Medical Center (TMC) system - Kansas City

Trial Details

FieldValue
Enrollment Target 804 participants
Start Date 2025-02-20
Est. Completion 2029-03
Phase NA
Emory University

1,208 total trials

What NCT06522022 shows while recruiting

NCT06522022 is an interventional study that assigns participants to a tested intervention. The registered 804 participants enrollment target is mid-sized for trials with a published cap, above the 297-participant average among 154 other PTSD trials with a reported enrollment target (171% higher).

The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Culturally Responsive SBIRT for OB is the first listed.

NCT06522022 reports a single indexed study location in Georgia, Missouri.

Frequently Asked Questions

What is clinical trial NCT06522022 about?

NCT06522022 is a clinical study titled "PTSD Screening in Pregnant Black Women". This study will compare the effectiveness of two active screening interventions in improving post-traumatic stress disorder (PTSD) symptoms, maternal perinatal care utilization, satisfaction utilization of mental healthcare services, and maternal health and birth-related outcomes for Black pregnant ...

What is the current status of trial NCT06522022?

This trial is currently recruiting. It is a NA study. The enrollment target is 804 participants. The study started on 2025-02-20. Estimated completion is 2029-03.

What conditions does trial NCT06522022 study?

This clinical trial studies the following conditions: PTSD, Pregnancy Early.

What interventions are being tested in trial NCT06522022?

The interventions under investigation include: Culturally Responsive SBIRT for OB (BEHAVIORAL), Brief Screening for PTSD (BEHAVIORAL).

Who is sponsoring clinical trial NCT06522022?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06522022 being conducted?

This trial has 2 study locations across Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06522022's enrollment target sits among peer trials

804 6th of 154 higher than 149 of 154 other PTSD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04423211 · 804 participants · Phase 3

    Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06065098 · 806 participants · NA

    Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

  • NCT03524430 · 801 participants · NA

    RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06522022, the US trial registry maintained by the National Library of Medicine. NCT06522022 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.